bluebird bio Inc.
BLUE
reported a loss of $2.94 per share in third-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of $3.07 and the year-ago quarter’s loss of $3.73.
Revenues of $19.3 million missed the Zacks Consensus Estimate of $26 million. The figure grew from $8.9 million in the year-ago quarter.
Shares of the company have decreased 33.3% year to date compared with the
industry
’s decline of 1.1%.
Quarter in Detail
R&D expenses decreased to $140.4 million from $151.4 million a year ago due to a decline in manufacturing costs.
Selling, general and administrative (SG&A) expenses of $68 million were up from $66.3 million in the year-ago quarter due to costs incurred to support the company’s ongoing operations and growth of its pipeline.
Pipeline Development
The company remains on track to complete the rolling biologics license application (BLA) submission for betibeglogene autotemcel (beti-cel; formerly LentiGlobin for β-thalassemia) in mid-2021.
In September 2020,bluebird and
Bristol Myers Squibb
BMY
announced that the FDA accepted for Priority Review their BLA for idecabtagene vicleucel (ide-cel; bb2121), the companies’ investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.The FDA set an action date of Mar 27, 2021.
In September 2020, the company announced that its investigational pipeline candidate for sickle cell disease (SCD) gene therapy, LentiGlobin, was granted eligibility to the Priority Medicines (PRIME) program by the European Medicines Agency (EMA).
Zacks Rank & Stocks to Consider
bluebirdis a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector are
Emergent BioSolutions Inc.
EBS
and
ADC Therapeutics SA
ADCT
. While Emergent carries a Zacks Rank #1 (Strong Buy), ADC Therapeutics carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank stocks here
.
Emergent’s earnings per share estimates have increased from $6.17 to $8.42 for 2021 in the past 60 days. Shares of the company have increased 82.2% year to date.
ADC Therapeutics’ loss per share estimates have narrowed from $4.37 to $4.32 for 2020 and from $3.19 to $3.08 for 2021 in the past 60 days. Shares of the company have increased 4.1% year to date.
bluebird bio, Inc. Price, Consensus and EPS Surprise
bluebird bio, Inc. price-consensus-eps-surprise-chart
|
bluebird bio, Inc. Quote
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking. Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
